ArticlePharmaceutical research2026
Residual Content Impacts Critical Quality Attributes and Performance of Risperidone Microspheres.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePoly (lactic-co-glycolic acid) (PLGA) microspheres are widely used long-acting injectable depots. However, their performance is highly sensitive to polymer material attributes that can influence microsphere structure, degradation, and drug release. While factors such as molecular weight and monomer ratio are well recognized, impact of residual species present in commercial PLGA has not been systematically evaluated. The novelty of the present study is the investigation of the effect of PLGA residual content on the physicochemical characteristics and in vitro performance of risperidone-loaded PLGA microspheres.
methodsPLGA with varying amounts of residual content was obtained either through purification of a high-residual polymer by reprecipitation or by deliberately spiking PLGA with controlled quantities of monomeric residues (lactide or glycolide) or organic solvent. Risperidone was selected as the model drug, and microsphere formulations were prepared using PLGA with different amounts of residual content and compared with microspheres prepared using low residual PLGA. The microspheres were characterized for particle size, surface morphology, porosity, drug loading, polymer degradation kinetics, and in vitro drug release.
resultsResidual content was shown to significantly influence microsphere formation and performance. High solvent residue had a great impact on microsphere particle size, porosity, and drug loading, resulting in accelerated polymer degradation and drug release. A clear correlation was established between residual content, microsphere structure, degradation behavior, and release kinetics.
conclusionsThese findings identify residual species as a critical material attribute of PLGA microspheres and highlight the importance of polymer purification and raw-material control to ensure consistent performance of microsphere formulations.
Indexed as
Identifiers
42141170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.